Breastmilk protein osteopontin found to boost infant immune defense against respiratory infections

4 min read
Source: abc.net.au
Breastmilk protein osteopontin found to boost infant immune defense against respiratory infections
Photo: abc.net.au
TL;DR

A five-year international study published in Cell reveals that osteopontin, a protein abundant in early breastmilk, triggers biological processes that strengthen infant immune systems against respiratory infections. Researchers at QIMR Berghofer Medical Research Institute found that this protein alters gut microbiomes and bacterial metabolites, which in turn activate growth factors in lung cells to boost immunity. While the study used mice, it suggests that adding osteopontin or mimicking its effects could improve commercial infant formulas. Experts note that while the science is foundational, human trials are needed, and improving breastfeeding support remains critical for public health outcomes.

Key points

  • Osteopontin, a protein found in high levels in early breastmilk, was identified as a key driver of immune system development in infants.
  • The study, led by Simon Phipps of QIMR Berghofer Medical Research Institute, demonstrated that osteopontin alters gut microbiomes, producing bacterial metabolites that activate immune growth factors in lung cells.
  • Mice fed osteopontin-concentrated cow's milk showed higher numbers of protective immune cells and better resistance to respiratory infections compared to those not receiving the protein.
  • Researchers discovered that a drug used for type 2 diabetes can mimic the immune-boosting effects of osteopontin, offering a potential pathway for formula enhancement.
  • The study was partially funded by Nestle and Australia's National Health and Medical Research Council, with ongoing discussions with infant formula companies to improve product quality.
  • Experts emphasize that while mouse studies are promising, human trials are necessary to confirm these mechanisms, and broader public health gains depend on improving access to breastfeeding support.

Background

This research builds on previous understanding that breastfeeding protects infants from respiratory infections, though the specific mechanisms were unclear. Unlike earlier studies focusing on general nutritional benefits, this work isolates the role of osteopontin and its interaction with the gut microbiome. It contrasts with recent findings on air filtration in care homes, which showed limited efficacy against viral infections, highlighting the importance of biological immune development in early life. The study also aligns with broader concerns about antibiotic-resistant infections, as strengthening innate immunity may reduce reliance on medical interventions for preventable diseases.

How outlets are covering it

The primary source, ABC News, highlights the potential for commercial infant formula improvements and the excitement surrounding the discovery of osteopontin's role. It emphasizes the collaboration between researchers and industry, noting discussions with formula companies. The secondary source, The Courier Mail, was inaccessible due to a bot detection block, so no additional perspective could be synthesized from it. However, the primary source includes views from independent experts like Professor Ben Desbrow, who praised the study as 'exceptional science' but noted its limitations in mouse models, and Associate Professor Valerie Slavin, who argued that the most significant public health gains would come from improving breastfeeding support systems rather than just formula modifications. These perspectives suggest a divide between the scientific potential for formula enhancement and the practical need for maternal support infrastructure.

Why it matters

Understanding the specific mechanisms by which breastmilk protects infants could lead to more effective infant formulas, potentially reducing respiratory infections in babies who cannot be breastfed. This could have long-term benefits for lung development and overall health. Additionally, the finding that a diabetes drug can mimic osteopontin's effects opens new avenues for therapeutic interventions. However, the study's reliance on mouse models means that human applications remain uncertain, and the broader impact depends on how well these findings translate to real-world infant health outcomes and formula manufacturing.

What to watch

Researchers are in discussions with infant formula companies to integrate findings into product development. Further human trials are needed to confirm the role of osteopontin in infant immunity. Public health experts are calling for increased investment in breastfeeding support systems to help mothers achieve their breastfeeding goals. The study's findings may also influence the development of new therapeutic approaches using existing drugs to mimic osteopontin's immune-boosting effects.

Share this article

Want the full story? Read the original reporting

Read on abc.net.au